Sanford C. Bernstein Reiterates Buy Rating for Bayer AG (BAYRY)
Other equities analysts also recently issued reports about the stock. DZ Bank AG reaffirmed a buy rating on shares of Bayer AG in a research note on Wednesday, May 25th. Commerzbank AG upgraded shares of Bayer AG from a hold rating to a buy rating in a report on Wednesday, May 25th. Deutsche Bank AG reiterated a buy rating on shares of Bayer AG in a report on Wednesday, May 25th. Goldman Sachs Group Inc. reiterated a buy rating on shares of Bayer AG in a report on Tuesday, May 24th. Finally, Citigroup Inc. upgraded shares of Bayer AG from a neutral rating to a buy rating in a report on Thursday, August 25th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $124.50.
Shares of Bayer AG (OTCMKTS:BAYRY) opened at 102.90 on Thursday. The firm has a market cap of $85.09 billion, a PE ratio of 16.84 and a beta of 1.40. Bayer AG has a 52 week low of $94.36 and a 52 week high of $135.71. The company’s 50-day moving average is $107.05 and its 200-day moving average is $107.71.
Bayer AG Company Profile
Bayer AG is a Germany-based chemical and pharmaceutical company. The Company’s business operations are organized into three segments: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. Bayer HealthCare researches, develops, manufactures and markets products to improve the health of people and animals.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.